Effects of Dronabinol (Oral THC) on Cannabis Use

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Study participants received dronabinol (0, 120mg/day and 240mg/day) for 12 consecutive days in a randomized order. During each dronabinol maintenance period they were able to self-administer active or placebo cannabis using either a progressive ratio schedule or choice between cannabis and monetary alternative.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Johns Hopkins University
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Dronabinol

Criteria

Inclusion Criteria:

• Current use of marijuana

• Able to give informed consent

Exclusion Criteria:

• Daily use of psychoactive medication

• Current Axis I psychiatric disorder other than dependence on cannabis or nicotine, or abuse of drugs or alcohol

• Women who are pregnant, breast feeding, or planning to become pregnant within the next 3 months

• Those seeking treatment for cannabis-related problems or using cannabis under the guidance of a physician for a medical disorder

• Uncontrolled or unstable cardiovascular disease

• Allergy to sesame oil